Activation of MAPK pathways due to DUSP4 loss promotes cancer stem cell-like phenotypes in basal-like breast cancer.
暂无分享,去创建一个
Phillip Owens | Rebecca S Cook | Carlos L Arteaga | Justin M Balko | H. Gómez | J. Balko | C. Arteaga | L. Schwarz | R. Cook | Phillip Owens | Richard I. J. Kurupi | T. Miller | Todd W Miller | Henry Gómez | N. Bhola | Luis J Schwarz | Neil E Bhola | Richard Kurupi
[1] Eric S. Lander,et al. Identification of Selective Inhibitors of Cancer Stem Cells by High-Throughput Screening , 2009, Cell.
[2] Christian A. Rees,et al. Molecular portraits of human breast tumours , 2000, Nature.
[3] D. Radisky,et al. TGFbeta/TNF(alpha)-mediated epithelial-mesenchymal transition generates breast cancer stem cells with a claudin-low phenotype. , 2011, Cancer research.
[4] S. Morrison,et al. Prospective identification of tumorigenic breast cancer cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[5] King-Jen Chang,et al. Multiple Lineages of Human Breast Cancer Stem/Progenitor Cells Identified by Profiling with Stem Cell Markers , 2009, PloS one.
[6] W. Hahn,et al. Human breast cancer cells generated by oncogenic transformation of primary mammary epithelial cells. , 2001, Genes & development.
[7] T. Beißbarth,et al. Mutated KRAS results in overexpression of DUSP4, a MAP‐kinase phosphatase, and SMYD3, a histone methyltransferase, in rectal carcinomas , 2010, Genes, chromosomes & cancer.
[8] Peter C. Hollenhorst,et al. Genome-wide analyses reveal properties of redundant and specific promoter occupancy within the ETS gene family. , 2007, Genes & development.
[9] Nicholas J. Wang,et al. Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. , 2009, Cancer research.
[10] J. Lachuer,et al. EMT Inducers Catalyze Malignant Transformation of Mammary Epithelial Cells and Drive Tumorigenesis towards Claudin-Low Tumors in Transgenic Mice , 2012, PLoS genetics.
[11] Jeffrey M. Rosen,et al. Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features , 2009, Proceedings of the National Academy of Sciences.
[12] M. Karin,et al. Identification of an oncoprotein- and UV-responsive protein kinase that binds and potentiates the c-Jun activation domain. , 1993, Genes & development.
[13] C. Sander,et al. V600EBRAF is associated with disabled feedback inhibition of RAF–MEK signaling and elevated transcriptional output of the pathway , 2009, Proceedings of the National Academy of Sciences.
[14] 宁北芳,et al. 疟原虫var基因转换速率变化导致抗原变异[英]/Paul H, Robert P, Christodoulou Z, et al//Proc Natl Acad Sci U S A , 2005 .
[15] Jason I. Herschkowitz,et al. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer , 2010, Breast Cancer Research.
[16] D. Miles,et al. Safety of bevacizumab (BV) plus docetaxel (D) in patients (pts) with locally recurrent (LR) or metastatic breast cancer (mBC) who developed brain metastases during the AVADO phase III study. , 2009 .
[17] Guy S. Salvesen,et al. SnapShot: Caspases , 2011, Cell.
[18] Wenjun Guo,et al. The Epithelial-Mesenchymal Transition Generates Cells with Properties of Stem Cells , 2008, Cell.
[19] M. Karin,et al. Oncogenic and transcriptional cooperation with Ha-Ras requires phosphorylation of c-Jun on serines 63 and 73 , 1991, Nature.
[20] F. Bertucci,et al. Aldehyde Dehydrogenase 1–Positive Cancer Stem Cells Mediate Metastasis and Poor Clinical Outcome in Inflammatory Breast Cancer , 2009, Clinical Cancer Research.
[21] Larry Norton,et al. Tumor Self-Seeding by Circulating Cancer Cells , 2009, Cell.
[22] A. Bosserhoff,et al. ETS‐1/RhoC signaling regulates the transcription factor c‐Jun in melanoma , 2012, International journal of cancer.
[23] A. Nobel,et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] P. Fortina,et al. p21CIP1 attenuates Ras- and c-Myc-dependent breast tumor epithelial mesenchymal transition and cancer stem cell-like gene expression in vivo , 2009, Proceedings of the National Academy of Sciences.
[25] Alberto Riva,et al. The MAPPER database: a multi-genome catalog of putative transcription factor binding sites , 2004, Nucleic Acids Res..
[26] Steven J. M. Jones,et al. Comprehensive molecular portraits of human breast tumours , 2013 .
[27] D. Santini,et al. IL-6 triggers malignant features in mammospheres from human ductal breast carcinoma and normal mammary gland. , 2007, The Journal of clinical investigation.
[28] Li Jin,et al. Genome amplification of single sperm using multiple displacement amplification , 2005, Nucleic acids research.
[29] John T. Wei,et al. Abstract 4707: Discovery and characterization of PCAT-1, a novel lincRNA implicated in prostate cancer tumorigenesis , 2011 .
[30] H. Lane,et al. Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells , 2009, Proceedings of the National Academy of Sciences.
[31] J. Balko,et al. MEK and EGFR inhibition demonstrate synergistic activity in EGFR-dependent NSCLC , 2009, Cancer biology & therapy.
[32] Benjamin E. Gross,et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. , 2012, Cancer discovery.
[33] Laura M. Heiser,et al. Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition. , 2009, Cancer research.
[34] M. de Silva,et al. Complex CGH alterations on chromosome arm 8p at candidate tumor suppressor gene loci in breast cancer cell lines. , 2005, Cancer genetics and cytogenetics.
[35] C. Mackay,et al. Targeting dual-specificity phosphatases: manipulating MAP kinase signalling and immune responses , 2007, Nature Reviews Drug Discovery.
[36] A. Puisieux,et al. Generation of Breast Cancer Stem Cells through Epithelial-Mesenchymal Transition , 2008, PloS one.
[37] E. Alba,et al. Lack of evidence for KRAS oncogenic mutations in triple-negative breast cancer , 2010, BMC Cancer.
[38] Adam A. Margolin,et al. The Cancer Cell Line Encyclopedia enables predictive modeling of anticancer drug sensitivity , 2012, Nature.
[39] G. Mills,et al. Profiling of residual breast cancers after neoadjuvant chemotherapy identifies DUSP4 deficiency as a mechanism of drug resistance , 2012, Nature Medicine.
[40] Wen-Lin Kuo,et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. , 2006, Cancer cell.
[41] G. Dontu,et al. In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. , 2003, Genes & development.
[42] Zhiyuan Hu,et al. Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors , 2007, Genome Biology.
[43] F. Khuri,et al. Oncogenic Ras and B-Raf Proteins Positively Regulate Death Receptor 5 Expression through Co-activation of ERK and JNK Signaling* , 2011, The Journal of Biological Chemistry.
[44] Steven J. M. Jones,et al. Comprehensive molecular portraits of human breast tumors , 2012, Nature.
[45] F. Bertucci,et al. Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. , 2009, Cancer research.
[46] Jason I. Herschkowitz,et al. The pINDUCER lentiviral toolkit for inducible RNA interference in vitro and in vivo , 2011, Proceedings of the National Academy of Sciences.
[47] Danila Coradini,et al. Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties. , 2005, Cancer research.
[48] M. Karin,et al. Ha-Ras augments c-Jun activity and stimulates phosphorylation of its activation domain , 1991, Nature.
[49] M. Camps,et al. Dual specificity phosphatases: a gene family for control of MAP kinase function , 2000, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[50] D. Birnbaum,et al. CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts. , 2010, The Journal of clinical investigation.
[51] Tao Zhang,et al. Aldehyde dehydrogenase 1 is a marker for normal and malignant human colonic stem cells (SC) and tracks SC overpopulation during colon tumorigenesis. , 2009, Cancer research.
[52] X. Chen,et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. , 2011, The Journal of clinical investigation.
[53] R Anbazhagan,et al. Allelic loss of chromosomal arm 8p in breast cancer progression. , 1998, The American journal of pathology.
[54] K. Gish,et al. Candidate tumor-suppressor genes on chromosome arm 8p in early-onset and high-grade breast cancers , 2004, Oncogene.
[55] R. Weinberg,et al. Epithelial Mesenchymal Transition Traits in Human Breast Cancer Cell Lines Parallel the CD44hi/CD24lo/- Stem Cell Phenotype in Human Breast Cancer , 2010, Journal of Mammary Gland Biology and Neoplasia.